Medscape August 27, 2024
(Reuters) – Eli Lilly said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month’s supply through its direct-to-consumer website to help increase its availability in the marketplace.
Zepbound is typically sold in auto-injector pens, but with easier to manufacture and fill vials Lilly will be able to get the drug to patients more quickly.
The 2.5 milligram and 5mg vials – the lowest doses of the drug – will cost $399 and $549 on its website LillyDirect, the company said.
That is a $250 discount, or 40%, for the lowest dose compared to the $650 per month Lilly now charges patients for...
Today's Sponsors
Today's Sponsor